Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in 'suboptimal' patients with advanced gastric cancer (AGC). TTD 08-02

Bibliographic Details
Title: Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in 'suboptimal' patients with advanced gastric cancer (AGC). TTD 08-02
Authors: Rivera, F., Massutí, B., Salcedo, M., Sastre, J., Martínez Galán, J., Valladares-Ayerbes, M., Serrano, R., Paredes, M. L., Manzano, J. L., Galán, M.
Source: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 75(2):319-324
Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN366333676&indx=1&recIds=ETOCRN366333676
Database: British Library Document Supply Centre Inside Serials & Conference Proceedings
More Details
ISSN:03445704
Published in:CANCER CHEMOTHERAPY AND PHARMACOLOGY
Language:English